NG
WX

NatWest Group’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

NatWest Group’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,698
Closed -$235 – 534
2014
Q3 		$235 Buy
+6,698
New +$230K ﹤0.01% 469

Other funds holding WX

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

NatWest Group's WX Position: Q4 2014 in Review

NatWest Group sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2014, closing a stake of 6,698 shares — an estimated $235 sold.

NatWest Group first reported a position in WX in Q3 2014 and held it in 1 quarter. The position peaked at $235 in Q3 2014. 165 funds tracked by Wall St. Rank hold WX as of Q4 2014.

  • NatWest Group reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2014 after selling out during the quarter.
  • NatWest Group sold 6,698 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2014, an estimated $235.
  • NatWest Group first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2014 and held it in 1 quarter.
  • NatWest Group's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $235 in Q3 2014.
  • 165 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2014.

Based on NatWest Group's 13F filing for Q4 2014, filed 12 Feb 2015.